

# ACT accelerator

ACCESS TO COVID-19 TOOLS

## Overview for WHO Member States

2 July 2020

## Key Dates

- 24 April** ACT-A Announced  
co-Hosts: WHO, EC, France, BMGF  
supporting: UN SG, Heads of State/Govt, agencies
- 4 May** EURO 9.8 B pledge event (incl. COVID response)
- 20 May** World Health Assembly Resolution
- 4 June** ACT-A Consolidated Roadmap
- 27 June** US\$ 6.9 B pledge event (incl. COVID response)

**The ACT goal:** reduce COVID19 mortality & severe disease through accelerated development, equitable allocation & scaled up delivery of...

### Vaccines



2 billion doses  
by the end of  
2021

### Therapeutics



245 million  
courses by  
mid-2021


### Diagnostics



500 million  
tests by mid-  
2021

...thereby protecting health systems & restoring societies & economies

# The ACT-Accelerator - Pillars drive the work



- **3 vertical Pillars** are the **primary drivers** of ACT's product work
- A cross-cutting **Access & Allocation Workstream** drives for equity
- A **Health Systems Connector** drives optimal utilization
- **Support mechanisms** incl. 2 Special Envoys, ACT VCs, ACT Support Hub

# ACT leverages the best of international health in coordination with WHO



**Coordination & Support**


**Cross-cutting Access & Allocation**

**All Pillars**

Norms & Standards  
Regulatory/PQ  
Policy & Technical guidance



## Vaccines



- Development & manufacturing
- Policy & allocation
- Procurement & delivery at scale

## Therapeutics



- Rapid assessment of candidates
- Market preparedness
- Deployment in all countries
- Costing & financing

## Diagnostics



- R&D
- Market readiness tools
- Supply
- Country preparedness


## Health Systems Connector




*In discussion*

- Country systems
- Integrated data mgmt
- Private sector
- Protect frontline workers
- Financing
- Key supply elements supply chain
- Clinical care
- Community-led responses

# WHO's most senior staff lead its engagement in ACT



# A high-level timeline communicates ACT's work



This high-level timeline anchors the comprehensive plans developed by the Pillars  
Work across the 4 Pillars would be adapted to the evolving epidemiology, trial results, and tools

# Core assumptions guide ACT's priorities

## Overarching assumptions

- **The substantial gaps in immunity to COVID-19 globally will result in continued & substantial waves of disease** through at least end-2021, straining health systems and further disrupting societies and economies
- **There are multiple potential approaches** to change spread & profile of COVID-19, thereby restoring functional societies & economies; further innovation is key to finding new solutions as NPI's alone will not be sufficient

## Vaccines

- An innovative-platform based **vaccine could be available by end-2020** but with limited supply; quantities for key sub-groups could be available in Q1-2 2021 with broader use and additional products from Q3 2021

## Therapeutics

- **New molecules or biologics, will be needed** to achieve significant reductions in mortality and/or morbidity (repurposing existing drugs is unlikely to be sufficient); these products may have higher costs, supply limitations and other access challenges

## Diagnostics

- **Expansion of PCR technologies** is the near term solution for the global diagnostics challenge; **innovation** (e.g., rapid antigen diagnostic) would substantially facilitate the global response

## Health systems strengthening

- Local capacities must be substantially strengthened to optimize in country delivery of new COVID-19 tools, including for 'the last mile'



# Key documents underpin the work of ACT


## Consolidated ACT Investment Case

Incl. Pillar targets & urgent financing needs over next 6 & 12 months



## Consolidated ACT Roadmap

Incl. goal, core assumptions, high-level timeline, deliverables





Released: 26 June 2020

Target date: mid-July 2020

# Financing the consolidated investment case

for the Vaccines, Therapeutics & Diagnostics Pillars (at 1 July 2020)



# The ACT Partnership – already delivering selected achievements since 24 April

- **9 vaccine** candidates already in COVAX portfolio; 6 in trials
- **Global COVAX Vaccines Facility** launched, 300 m doses already secured & Advance Market Commitment (AMC) issued
- **1 new therapeutic** demonstrated effectiveness
- **50+ test kits** under evaluations & **10+ million kits** procured
- **Ethical Access Principles** agreed and **Allocation Framework** under consultation with Member States

# The ACT Accelerator Call to Action

## Our Commitment

1. We commit to the shared aim of equitable global access to innovative tools for COVID-19 for all.
2. We commit to an unprecedented level of partnership – proactively engaging stakeholders, aligning and coordinating efforts, building on existing collaborations, collectively devising solutions, and grounding our partnership in transparency, and science.
3. We commit to create a strong unified voice to maximize impact, recognizing this is not about singular decision-making authority, but rather collective problem-solving, interconnectedness and inclusivity, where all stakeholders can connect and benefit from the expertise, knowledge and activities of this shared action-oriented platform.
4. We commit to build on past experiences towards achieving this objective, including ensuring that every activity we undertake is executed through the lens of equitable global access, and that the voices of the communities most affected are heard.
5. We commit to be accountable to the world, to communities, and to one another. We are coming together in the spirit of solidarity, and in the service of humanity, to achieve our mission and vision.



“We ask **the global community and political leaders to support this landmark collaboration**, and for donors to provide the necessary resources to accelerate achievement of the objectives of this global collaboration.”

## Further information:

[ACTaccelerator@who.int](mailto:ACTaccelerator@who.int)